Law360, New York (July 27, 2009) -- A Medarex Inc. investor has sued Medarex, its board of directors and Bristol-Myers Squibb Co., alleging that Bristol-Myers’ plans to acquire the biologics company in a $2.1 billion deal are both procedurally and financially unfair to shareholders.
Kenneth Blumberg filed a putative shareholder class action Thursday in the U.S. District Court for the District of New Jersey, alleging that Medarex and Bristol-Myers induced Medarex’s board of directors...
